Cure Pharmaceutical, a drug delivery and development company, has announced it has signed a deal with Oklahoma-based hemp grower Fytiko Farms. The deal gives Cure direct, guaranteed access to high-quality plant material for exclusive use in its proprietary oral thin film drug delivery system, CUREfilm.
“The agreement with Fytiko Farms is a crucial step in CURE’s effort to secure our CBD supply chain and also includes preferred pricing for CURE,” said Rob Davidson, CEO of CURE Pharmaceutical. “Our next step will be securing a relationship with vendors for the extraction process leveraging our extraction patents.”
According to them, the deal provides access to high-quality organic hemp extracts for use in CURE products through strain improvement, cannabinoid extraction process development, biomarker identification and quality control testing.
“Partnering with CURE allows us to expand into more markets and grow our production capabilities,” said Joe Dan Rogers, CEO of Fytiko Farms. “This partnership supports our main business of growing hemp by providing a production hub for local farmers and marketing our high-quality hemp oil and other byproducts for use in CURE’s hemp-based products.”
Fytiko Farms is a company focused on industrial hemp production, cultivation, seed and clone production and sale and the processing and sale of the various by-products from the hemp plant. In 2019, Fytiko Farms was licensed to plant in Oklahoma, utilizing select varieties specifically targeted for their genetics.
For more information:
Cure Pharmaceutical
1620 Beacon Place
Oxnard, CA 93033
Phone: (805) 824-0410
Fax: (805) 487-7163
curepharmaceutical.com